These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1603340)

  • 1. Therapeutic bioequivalency study of brand name versus generic carbamazepine.
    Oles KS; Penry JK; Smith LD; Anderson RL; Dean JC; Riela AR
    Neurology; 1992 Jun; 42(6):1147-53. PubMed ID: 1603340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalency revisited: epitol versus tegretol.
    Oles KS; Gal P
    Neurology; 1993 Dec; 43(12):2435-6. PubMed ID: 8255435
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients.
    Silpakit O; Amornpichetkoon M; Kaojarern S
    Ann Pharmacother; 1997 May; 31(5):548-52. PubMed ID: 9161646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard.
    Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE
    Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of steady-state blood levels of two carbamazepine formulations.
    Jumao-as A; Bella I; Craig B; Lowe J; Dasheiff RM
    Epilepsia; 1989; 30(1):67-70. PubMed ID: 2912719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group.
    Neurology; 1995 Sep; 45(9):1703-7. PubMed ID: 7675230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy.
    Hartley R; Aleksandrowicz J; Bowmer CJ; Cawood A; Forsythe WI
    J Pharm Pharmacol; 1991 Feb; 43(2):117-9. PubMed ID: 1672895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind randomized study comparing brand-name and generic phenytoin monotherapy.
    Mikati M; Bassett N; Schachter S
    Epilepsia; 1992; 33(2):359-65. PubMed ID: 1547767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamazepine toxicity resulting from generic substitution.
    Gilman JT; Alvarez LA; Duchowny M
    Neurology; 1993 Dec; 43(12):2696-7. PubMed ID: 8255480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of carbamazepine. Part I: A new bioequivalency parameter based on a relative bioavailability trial.
    Kayali A; Tuğlular I; Ertaş M
    Eur J Drug Metab Pharmacokinet; 1994; 19(4):319-25. PubMed ID: 7737233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative bioavailability and steady state fluctuations of Tegretol commercial and carbamazepine OROS tablets in adult and pediatric epileptic patients.
    Thakker KM; Mangat S; Garnett WR; Levy RH; Kochak GM
    Biopharm Drug Dispos; 1992 Nov; 13(8):559-69. PubMed ID: 1421050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in serum concentrations of and responses to generic verapamil in the elderly.
    Carter BL; Noyes MA; Demmler RW
    Pharmacotherapy; 1993; 13(4):359-68. PubMed ID: 8361862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the efficacy of Tegatard and Tegretol as a monotherapy in patients with focal seizure with or without secondary generalization.
    Najafi MR; Najafi MA; Shayan-Moghadam R; Saadatpour Z; Ghadimi K
    Am J Clin Exp Immunol; 2020; 9(4):58-63. PubMed ID: 33235821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of absorption rate and bioavailability of two brands of carbamazepine.
    Revankar SN; Desai ND; Bhatt AD; Bolar HV; Sane SP; Gupta C; Kamat DV
    J Assoc Physicians India; 1999 Jul; 47(7):699-702. PubMed ID: 10778590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonazepam (Rivotril) and carbamazepine (Tegretol) in psychomotor epilepsy: a randomized multicenter trial.
    Mikkelsen B; Berggreen P; Joensen P; Kristensen O; Køhler O; Mikkelsen BO
    Epilepsia; 1981 Aug; 22(4):415-20. PubMed ID: 7021140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
    Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
    Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are generic drugs really inferior medicines?
    Moore N; Berdaï D; Bégaud B
    Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double dummy comparison between once and twice daily dosing with modified-release carbamazepine in epileptic patients.
    McKee PJ; Blacklaw J; Carswell A; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1993 Sep; 36(3):257-61. PubMed ID: 9114913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with conventional and controlled-release carbamazepine: a double-blind, double-dummy comparison in epileptic patients.
    McKee PJ; Blacklaw J; Butler E; Gillham RA; Brodie MJ
    Br J Clin Pharmacol; 1991 Jul; 32(1):99-104. PubMed ID: 1888646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative bioavailability of four Carbamazepine tablet formulations available in the Kenyan market.
    Oluka MO; Mitema ES; Kibwage IO; Kwasa TO; Kokwaro GO
    East Afr Med J; 1996 May; 73(5):323-6. PubMed ID: 8756037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.